Outbreak response teams finally have a reliable way to determine who has been vaccinated against Ebola versus who survived natural infection—a distinction critical for tracking both vaccine coverage and disease spread during epidemics. The challenge has long been that standard antibody tests couldn't tell the difference between these two very different types of immunity.
Researchers developed a multiplex blood test that simultaneously detects three distinct markers: the standard Ebola glycoproteins, secreted glycoproteins specific to wild virus, and vesicular stomatitis virus proteins unique to the ERVEBO vaccine vector. Testing samples from US vaccine recipients and controls, plus field samples from Democratic Republic of Congo, the assay achieved 100% sensitivity and over 97% specificity for identifying vaccinated individuals. In Guinea field samples following ring vaccination campaigns, the combined markers confirmed vaccination status in 95% of people with written documentation and 91% with verbal confirmation.
This breakthrough addresses a fundamental surveillance gap that has hampered outbreak response efforts. During Ebola epidemics, distinguishing vaccine-induced immunity from infection-acquired immunity determines everything from contact tracing strategies to population-level protection assessments. Previous serologic tools essentially rendered vaccination records unreliable once antibodies appeared, forcing teams to rely on often incomplete paper documentation. The new assay's incorporation of vaccine vector-specific proteins provides an immunological fingerprint that persists alongside traditional Ebola antibodies. For public health preparedness, this represents a significant advance in real-time epidemic intelligence, enabling more precise targeting of vaccination efforts and more accurate assessment of community protection levels during active outbreaks.